| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| M S Nobler, J J Mann, H A Sackei. Serotonin, cerebral blood flow, and cerebral metabolic rate in geriatric major depression and normal aging. Brain research. Brain research reviews. vol 30. issue 3. 2000-01-05. PMID:10567727. |
serotonin, cerebral blood flow, and cerebral metabolic rate in geriatric major depression and normal aging. |
2000-01-05 |
2023-08-12 |
Not clear |
| J C Alvarez, N Gluck, I Arnulf, P Quintin, M Leboyer, R Pecquery, J M Launay, F Perez-Diaz, O Spreux-Varoquau. Decreased platelet serotonin transporter sites and increased platelet inositol triphosphate levels in patients with unipolar depression: effects of clomipramine and fluoxetine. Clinical pharmacology and therapeutics. vol 66. issue 6. 2000-01-04. PMID:10613618. |
decreased platelet serotonin transporter sites and increased platelet inositol triphosphate levels in patients with unipolar depression: effects of clomipramine and fluoxetine. |
2000-01-04 |
2023-08-12 |
human |
| U Müller, T Murai, T Bauer-Wittmund, D Y von Cramo. Paroxetine versus citalopram treatment of pathological crying after brain injury. Brain injury. vol 13. issue 10. 2000-01-03. PMID:10576464. |
selective serotonin reuptake inhibitors (ssris) are the treatment of choice for pathological crying after brain injury, independent of accompanying depression. |
2000-01-03 |
2023-08-12 |
Not clear |
| W C Drevets, E Frank, J C Price, D J Kupfer, D Holt, P J Greer, Y Huang, C Gautier, C Mathi. PET imaging of serotonin 1A receptor binding in depression. Biological psychiatry. vol 46. issue 10. 1999-12-29. PMID:10578452. |
pet imaging of serotonin 1a receptor binding in depression. |
1999-12-29 |
2023-08-12 |
human |
| D Owen, L Du, D Bakish, Y D Lapierre, P D Hrdin. Norepinephrine transporter gene polymorphism is not associated with susceptibility to major depression. Psychiatry research. vol 87. issue 1. 1999-12-27. PMID:10512149. |
the mechanism of action of certain antidepressant drugs, particularly the tricyclics and the newly available norepinephrine and serotonin reuptake inhibitors (nsris) drugs, venlafaxine and nefazodone, suggest that the norepinephrine transporter, which is a target for these antidepressant drugs, and its malfunction may be involved in major depression. |
1999-12-27 |
2023-08-12 |
human |
| L Arborelius, C Wallsten, S Ahlenius, T H Svensso. The 5-HT(1A) receptor antagonist robalzotan completely reverses citalopram-induced inhibition of serotonergic cell firing. European journal of pharmacology. vol 382. issue 2. 1999-12-17. PMID:10528148. |
5-ht(1a) receptor antagonists have been suggested to increase the efficacy of selective serotonin (5-hydroxytryptamine; 5-ht) reuptake inhibitors in the treatment of depression by enhancing the increase in brain 5-ht induced by 5-ht reuptake blockade. |
1999-12-17 |
2023-08-12 |
rat |
| L Arborelius, C Wallsten, S Ahlenius, T H Svensso. The 5-HT(1A) receptor antagonist robalzotan completely reverses citalopram-induced inhibition of serotonergic cell firing. European journal of pharmacology. vol 382. issue 2. 1999-12-17. PMID:10528148. |
thus, robalzotan may be effective by enhancing the action of selective 5-ht reuptake inhibitors or as monotherapy in the treatment of depression. |
1999-12-17 |
2023-08-12 |
rat |
| C C Meltzer, J C Price, C A Mathis, P J Greer, M N Cantwell, P R Houck, B H Mulsant, D Ben-Eliezer, B Lopresti, S T DeKosky, C F Reynold. PET imaging of serotonin type 2A receptors in late-life neuropsychiatric disorders. The American journal of psychiatry. vol 156. issue 12. 1999-12-14. PMID:10588399. |
to determine whether there are abnormalities in the in vivo status of the serotonin type 2a (5-ht2a) receptor in late-life depression and alzheimer's disease, the authors used positron emission tomography (pet) to assess patients with these two conditions and healthy subjects. |
1999-12-14 |
2023-08-12 |
human |
| S M Southwick, S Paige, C A Morgan, J D Bremner, J H Krystal, D S Charne. Neurotransmitter alterations in PTSD: catecholamines and serotonin. Seminars in clinical neuropsychiatry. vol 4. issue 4. 1999-12-13. PMID:10553029. |
evidence of serotonergic dysregulation in ptsd includes frequent symptoms of aggression, impulsivity, depression and suicidality, decreased platelet paroxetine binding, blunted prolactin response to fenfluramine, exaggerated reactivity to m-chloro-phenyl-piperazine, and clinical efficacy of serotonin reuptake inhibitors. |
1999-12-13 |
2023-08-12 |
Not clear |
| Y J Karten, S M Nair, L van Essen, R Sibug, M Joël. Long-term exposure to high corticosterone levels attenuates serotonin responses in rat hippocampal CA1 neurons. Proceedings of the National Academy of Sciences of the United States of America. vol 96. issue 23. 1999-12-13. PMID:10557342. |
in the present animal study, we tested one possible mechanism, i.e., that long-term exposure to high corticosterone levels alters functional responses to serotonin in the hippocampus, an important area in the etiology of depression. |
1999-12-13 |
2023-08-12 |
rat |
| Y J Karten, S M Nair, L van Essen, R Sibug, M Joël. Long-term exposure to high corticosterone levels attenuates serotonin responses in rat hippocampal CA1 neurons. Proceedings of the National Academy of Sciences of the United States of America. vol 96. issue 23. 1999-12-13. PMID:10557342. |
the present findings indicate that prolonged elevation of the corticosteroid concentration, a possible causal factor for major depression in humans, gradually attenuates responsiveness to serotonin without necessarily decreasing serotonin-1a receptor mrna levels in pyramidal neurons. |
1999-12-13 |
2023-08-12 |
rat |
| B Grimaldi, A Bonnin, M P Fillion, N Prudhomme, G Fillio. 5-Hydroxytryptamine-moduline: a novel endogenous peptide involved in the control of anxiety. Neuroscience. vol 93. issue 4. 1999-12-09. PMID:10501445. |
indeed, serotonin is involved in a large number of physiological events, such as temperature regulation, sleep, learning and memory, behaviour, sexual function, hormonal secretions and immune activity, and in parallel, it is also implicated in pathological disorders particularly in stress, anxiety, aggressivity and depression. |
1999-12-09 |
2023-08-12 |
mouse |
| A Mizruchin, I Gold, I Krasnov, G Livshitz, R Shahin, A I Koo. Comparison of the effects of dopaminergic and serotonergic activity in the CNS on the activity of the immune system. Journal of neuroimmunology. vol 101. issue 2. 1999-12-09. PMID:10580803. |
only depressive patients demonstrated low natural killer (nk) cell activity, which is inversely correlated to the intensity of depression and could be reversed by serotonin selective re-uptake inhibitors concomitant with clinical improvement. |
1999-12-09 |
2023-08-12 |
Not clear |
| S Jones, J A Kaue. Amphetamine depresses excitatory synaptic transmission via serotonin receptors in the ventral tegmental area. The Journal of neuroscience : the official journal of the Society for Neuroscience. vol 19. issue 22. 1999-12-02. PMID:10559387. |
unexpectedly, this depression is mediated not by activation of dopamine receptors, but instead by activation of serotonin receptors. |
1999-12-02 |
2023-08-12 |
Not clear |
| J L Cummings, D L Masterma. Depression in patients with Parkinson's disease. International journal of geriatric psychiatry. vol 14. issue 9. 1999-11-23. PMID:10479741. |
selective serotonin reuptake inhibitors have comparable efficacy to the tcas and a better tolerability profile in patients with depression; they are rapidly being considered as first-line therapy for pd patients with depression. |
1999-11-23 |
2023-08-12 |
Not clear |
| D J Nutt, S Forshall, C Bell, A Rich, J Sandford, J Nash, S Argyropoulo. Mechanisms of action of selective serotonin reuptake inhibitors in the treatment of psychiatric disorders. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 9 Suppl 3. 1999-11-23. PMID:10523062. |
selective serotonin reuptake inhibitors (ssris) have demonstrated efficacy in depression and anxiety disorders. |
1999-11-23 |
2023-08-12 |
Not clear |
| D J Nutt, S Forshall, C Bell, A Rich, J Sandford, J Nash, S Argyropoulo. Mechanisms of action of selective serotonin reuptake inhibitors in the treatment of psychiatric disorders. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 9 Suppl 3. 1999-11-23. PMID:10523062. |
tryptophan depletion has been used extensively in research into depression and has shown that, in patients receiving an ssri whose depression is in remission, depleting serotonin leads to recurrence of the disorder. |
1999-11-23 |
2023-08-12 |
Not clear |
| D J Nutt, S Forshall, C Bell, A Rich, J Sandford, J Nash, S Argyropoulo. Mechanisms of action of selective serotonin reuptake inhibitors in the treatment of psychiatric disorders. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 9 Suppl 3. 1999-11-23. PMID:10523062. |
this suggests that increased levels of serotonin are necessary in the synapse for the ssri to be effective in the treatment of depression and panic disorder. |
1999-11-23 |
2023-08-12 |
Not clear |
| M Isaa. Where are we going with SSRIs? European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 9 Suppl 3. 1999-11-23. PMID:10523065. |
during the past decade the selective serotonin reuptake inhibitors (ssris) have become established as the treatment of choice for depression. |
1999-11-23 |
2023-08-12 |
Not clear |
| C Lundkvist, C Loc'h, C Halldin, M Bottlaender, M Ottaviani, C Coulon, C Fuseau, C Mathis, L Farde, B Mazièr. Characterization of bromine-76-labelled 5-bromo-6-nitroquipazine for PET studies of the serotonin transporter. Nuclear medicine and biology. vol 26. issue 5. 1999-11-22. PMID:10473188. |
the development of suitable radioligands for brain imaging of the serotonin transporter is of great importance for the study of depression and other affective disorders. |
1999-11-22 |
2023-08-12 |
rat |